Total submissions: 16
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001080083 | SCV000073869 | likely benign | Hereditary breast ovarian cancer syndrome | 2024-01-27 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000128972 | SCV000172857 | benign | Hereditary cancer-predisposing syndrome | 2015-01-15 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Gene |
RCV000587951 | SCV000210553 | likely benign | not provided | 2021-01-15 | criteria provided, single submitter | clinical testing | This variant is associated with the following publications: (PMID: 10923033, 11929857, 20104584, 25479140, 21520273, 31131967) |
Counsyl | RCV000083161 | SCV000487870 | uncertain significance | Breast-ovarian cancer, familial, susceptibility to, 2 | 2015-11-24 | criteria provided, single submitter | clinical testing | |
Department of Pathology and Molecular Medicine, |
RCV000045856 | SCV000588074 | uncertain significance | not specified | 2017-04-20 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000045856 | SCV000695252 | likely benign | not specified | 2023-05-01 | criteria provided, single submitter | clinical testing | Variant summary: BRCA2 c.956A>G (p.Asn319Ser) results in a conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 1.7e-05 in 229618 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.956A>G has been reported in the literature in individuals with pancreatic cancer (Grant_2015, Power_2021) and in at least one individual affected with unilateral breast cancer (Borg_2010, Capanu_2010) without strong evidence for causality. These reports do not provide unequivocal conclusions about association of the variant with Hereditary Breast And Ovarian Cancer Syndrome. A large scale multifactorial quantitative analysis to support clinical variant classification has rendered a likely benign outcome (Parsons_2019). One publication reports experimental evidence evaluating an impact on CDC25A mRNA expression, however, does not allow convincing conclusions about the variant effect (Biswas_2018). The following publications have been ascertained in the context of this evaluation (PMID: 29416040, 20104584, 21520273, 25479140, 28132688, 31131967, 32918181, 30212499, 11929857). Ten submitters have provided clinical-significance assessments for this variant to ClinVar after 2014 with a majority consensus leaning towards a benign(n=2)/likely benign (n=5) outcome (VUS, n=3). Based on the evidence outlined above, the variant was classified as likely benign. |
Color Diagnostics, |
RCV000128972 | SCV000902830 | benign | Hereditary cancer-predisposing syndrome | 2016-01-05 | criteria provided, single submitter | clinical testing | |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000587951 | SCV001133986 | likely benign | not provided | 2021-06-23 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV001109313 | SCV001266635 | uncertain significance | Fanconi anemia complementation group D1 | 2018-01-15 | criteria provided, single submitter | clinical testing | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. |
Illumina Laboratory Services, |
RCV000083161 | SCV001266636 | uncertain significance | Breast-ovarian cancer, familial, susceptibility to, 2 | 2018-01-15 | criteria provided, single submitter | clinical testing | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. |
Sema4, |
RCV000128972 | SCV002532049 | likely benign | Hereditary cancer-predisposing syndrome | 2022-03-17 | criteria provided, single submitter | curation | |
University of Washington Department of Laboratory Medicine, |
RCV000128972 | SCV003848162 | likely benign | Hereditary cancer-predisposing syndrome | 2023-03-23 | criteria provided, single submitter | curation | Missense variant in a coldspot region where missense variants are very unlikely to be pathogenic (PMID:31911673). |
Sharing Clinical Reports Project |
RCV000083161 | SCV000115235 | likely benign | Breast-ovarian cancer, familial, susceptibility to, 2 | 2009-02-13 | no assertion criteria provided | clinical testing | |
Breast Cancer Information Core |
RCV000083161 | SCV000145793 | uncertain significance | Breast-ovarian cancer, familial, susceptibility to, 2 | 2004-02-20 | no assertion criteria provided | clinical testing | |
Department of Pathology and Laboratory Medicine, |
RCV000587951 | SCV000591721 | uncertain significance | not provided | no assertion criteria provided | clinical testing | The p.Asn319Ser variant has been previously observed in our laboratory, and has been reported in the literature in 2/8412 proband chromosomes of individuals with breast cancer and in 3/8586 control chromosomes tested (Borg 2010, Warren 2002, Capanu_2011_). It is listed in the dbSNP database as coming from a "clinical source" (ID#:rs55939572), but no frequency information was provided, and so the prevalence of this variant in the population is not known. It has been observed in the BIC (x9) and Exome Variant Server databases. The p.Asn319 residue is conserved in mammals, and the variant Serine (Ser) is present in the chicken at this position, increasing the likelihood that an alteration to this residue may not have functional significance. Computational analyses (PolyPhen, SIFT, AlignGVGD) do not predict any effect on the protein function, though this information is not very predictive of pathogenicity. In summary, based on the above information the clinical significance of this variant cannot be determined at this time. Therefore this variant is a variant of unknown significance. | |
Foulkes Cancer Genetics LDI, |
RCV000735630 | SCV000863768 | uncertain significance | Breast and/or ovarian cancer | 2012-10-18 | no assertion criteria provided | clinical testing |